PACB
Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.
Pacific Biosciences of California, Inc. (PACB) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Profitability (C-). The rating has held at C+ for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | C (2.3) | C- (1.9) | A (4.3) | C+ (2.6) | C+ (2.8) |
| 2026-11-07 | B- (3.0) | C (2.3) | D (1.4) | A (4.3) | C+ (2.7) | C+ (2.7) |
| 2026-10-31 | B (3.2) | C (2.2) | D (1.5) | A (4.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-24 | B (3.2) | C (2.2) | D (1.5) | B (3.2) | C+ (2.6) | C+ (2.5) |
| 2026-10-17 | B (3.2) | C (2.2) | D (1.5) | C+ (2.7) | C+ (2.6) | C (2.5) |